Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Price, EPS and Revenue Projections
Strong Buy
0
Buy
0
Hold
6
Sell
2
Strong Sell
2
updated on
Dec 03, 2025
No. of Analysts
1Y Price Target
Q3 EPS Estimate
Q3 Revenue Estimate
Bearish
4
Neutral
3
Bullish
7
Bearish
36
Neutral
3
Bullish
7
Bearish
32
Neutral
0
Bullish
0
Investor Presentation
Q2 FY25
Investor Presentation
Q4 FY24
Get In-depth insights on EPS and Revenue forecasts
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone

Market Cap
₹ 2,289 Cr
P/E
—
Regulatory Filing
17 hours ago
Disclosure of Share Acquisition by Kare Family Pvt Trust
The Kare Family Pvt Trust disclosed its acquisition of 14.20% equity shares in Indoco Remedies Limited under SEBI regulations regarding substantial share acquisitions.
Press Release
4 days ago
Indoco Receives USFDA Establishment Inspection Report
Indoco Remedies Limited has received the Establishment Inspection Report from the USFDA for its API manufacturing facility in Patalganga, highlighting compliance with quality standards.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
2,289 Cr
Low Risk
—
30.8
—
2.3
348.60
190.00
Sales CAGR
1Y
-8.38%
3Y
-0.47%
5Y
6.54%
10Y
4.69%
Profit CAGR
1Y
-180.36%
3Y
—
5Y
—
10Y
—
ROE
TTM
-11.28%
3Y
5.29%
5Y
8.59%
10Y
7.88%
ROCE
TTM
-2.11%
3Y
8.74%
5Y
12.40%
10Y
11.08%
Performance
UNDER PERFORMER
Valuation
REASONABLE
Growth
STABLE
Profitability
LOW MARGIN
Technicals
Bearish
Risk
MODERATE RISK